LIAN Group, a dynamic investor and operator known for its significant investments in the healthcare sector, has announced the acquisition of Scientis, a pioneering Swiss cosmeceutical company. The acquisition marks a strategic expansion of LIAN Group’s healthcare platform, which already includes the #1 Swiss dentistry network, Cheeze, and signals the group’s intent to broaden its reach within the beauty and wellbeing sectors.
Scientis, a dermatology company based in Switzerland, specialises in addressing skin pigmentation issues. Its flagship product, Cyspera®, is renowned for its proprietary Cysteamine Isobionic-Amide Complex™, a clinically proven pigment corrector. The unique formulation of Cyspera® leverages potent antioxidant properties, making it the first topical product designed specifically to target uneven skin tone and discolouration. With an already strong presence in key markets such as Asia and the United States, Scientis is well-positioned for further global expansion.
Commenting on the acquisition, Fiorenzo Manganiello, Managing Partner of LIAN Group, expressed enthusiasm for the new partnership. “We are thrilled to welcome Scientis to LIAN Group’s healthcare platform. Our commitment is to accelerate Scientis’ growth by leveraging our network, expertise, and resources to explore new markets, streamline operations, and develop innovative products and services. We aim to empower both patients and healthcare professionals with high-quality solutions,” Manganiello stated.
The acquisition of Scientis underscores LIAN Group’s broader strategy to enhance its presence in the healthcare sector by venturing beyond its established dentistry business. With this latest move, LIAN Group plans to further expand its investments within the beauty and wellbeing industries, with more acquisitions anticipated in the near future.
The core team at LIAN Group will work closely with Scientis to unlock new markets and optimise the company’s operations. Together, they aim to develop new offerings that not only meet the evolving needs of patients but also provide valuable tools and products for healthcare professionals. This collaborative approach is intended to strengthen Scientis’ position in the global market and drive its continued success.
As LIAN Group continues to diversify its investment portfolio, the acquisition of Scientis represents a significant step forward in its mission to deliver leading healthcare solutions across various industries. With its strategic focus on innovation and growth, LIAN Group is set to play a key role in shaping the future of the healthcare and cosmeceutical sectors.